nach oben

Clinical and Experimental Medicine

Erschienen in:

18.08.2017 | Original Article

Nonassociation of homocysteine gene polymorphisms with treatment outcome in South Indian Tamil Rheumatoid Arthritis patients

verfasst von: Niveditha Muralidharan, Reena Gulati, Durga Prasanna Misra, Vir S. Negi

Erschienen in: Clinical and Experimental Medicine | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

The aim of the study was to look for any association of MTR 2756A>G and MTRR 66A>G gene polymorphisms with clinical phenotype, methotrexate (MTX) treatment response, and MTX-induced adverse events in South Indian Tamil patients with rheumatoid arthritis (RA). A total of 335 patients with RA were investigated. MTR 2756A>G gene polymorphism was analyzed by PCR–RFLP, and MTRR 66A>G SNP was analyzed by TaqMan 5′ nuclease assay. The allele frequencies were compared with HapMap groups. MTR 2756G allele was found to be associated with risk of developing RA. The allele frequencies of MTR 2756A>G and MTRR 66A>G SNPs in controls differed significantly when compared with HapMap groups. Neither of the SNPs influenced the MTX treatment outcome and adverse effects. Neither of the SNPs seems to be associated with MTX treatment outcome and adverse events in South Indian Tamil patients with RA.

Nur mit Berechtigung zugänglich

Holers VM. Autoimmunity to citrullinated proteins and the initiation of rheumatoid arthritis. Curr Opin Immunol. 2013;25:728–35.CrossRefPubMedPubMedCentral

Deane KD. Can rheumatoid arthritis be prevented? Best Pract Res Clin Rheumatol. 2013;27:467–85.CrossRefPubMedPubMedCentral

Tobón GJ, Youinou P, Saraux A. The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. Autoimmun Rev. 2010;9:A288–92.CrossRefPubMed

Tanaka Y. Current concepts in the management of rheumatoid arthritis. Korean J Intern Med. 2016;31:210–8.CrossRefPubMedPubMedCentral

Vivar N, Van Vollenhoven RF. Advances in the treatment of rheumatoid arthritis. F1000prime Rep. 2014;6:31.CrossRefPubMedPubMedCentral

McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205–19.CrossRefPubMed

Colmegna I, Ohata BR, Menard HA. Current understanding of rheumatoid arthritis therapy. Clin Pharmacol Ther. 2012;91:607–20.CrossRefPubMed

Wesoly J, Wessels JAM, Guchelaar H-J, Huizinga TWJ. Genetic markers of treatment response in rheumatoid arthritis. Curr Rheumatol Rep. 2006;8:369–77.CrossRefPubMed

Ranganathan P, McLeod HL. Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum. 2006;54:1366–77.CrossRefPubMed

10.

Burgos PI, Danila MI, Kelley JM, Hughes LB, Bridges SL. Understanding personalized medicine in rheumatoid arthritis: a clinician’s guide to the future. Ther Adv Musculoskelet Dis. 2009;1:97–105.CrossRefPubMedPubMedCentral

11.

Hider SL, Bruce IN, Thomson W. The pharmacogenetics of methotrexate. Rheumatol Oxf Engl. 2007;46:1520–4.CrossRef

12.

Spyridopoulou KP, Dimou NL, Hamodrakas SJ, Bagos PG. Methylene tetrahydrofolate reductase gene polymorphisms and their association with methotrexate toxicity: a meta-analysis. Pharmacogenet Genomics. 2012;22:117–33.CrossRefPubMed

13.

Owen SA, Lunt M, Bowes J, Hider SL, Bruce IN, Thomson W, et al. MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms. Pharmacogenomics J. 2013;13:137–47.CrossRefPubMed

14.

Bohanec Grabar P, Logar D, Lestan B, Dolzan V. Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. Eur J Clin Pharmacol. 2008;64:1057–68.CrossRefPubMed

15.

Wessels JAM, Kooloos WM, De Jonge R, De Vries-Bouwstra JK, Allaart CF, Linssen A, et al. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 2006;54:2830–9.CrossRefPubMed

16.

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569–81.CrossRefPubMed

17.

Van Gestel AM, Prevoo ML, van’t Hof MA, van’t Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39:34–40.CrossRefPubMed

18.

Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.CrossRefPubMedPubMedCentral

19.

Skibola CF, Smith MT, Hubbard A, Shane B, Roberts AC, Law GR, et al. Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. Blood. 2002;99:3786–91.CrossRefPubMed

20.

Waseem M, Hussain SR, Kumar S, Serajuddin M, Mahdi F, Sonkar SK, et al. Association of MTHFR (C677T) gene polymorphism with breast cancer in North India. Biomark Cancer. 2016;8:111–7.CrossRefPubMedPubMedCentral

21.

Nikbakht M, MalekZadeh K, Kumar Jha A, Askari M, Marwaha RK, Kaul D, et al. Polymorphisms of MTHFR and MTR genes are not related to susceptibility to childhood ALL in North India. Exp Oncol. 2012;34:43–8.PubMed

22.

Zhang Z, Shi Q, Liu Z, Sturgis EM, Spitz MR, Wei Q. Polymorphisms of methionine synthase and methionine synthase reductase and risk of squamous cell carcinoma of the head and neck: a case-control analysis. Cancer Epidemiol Biomark Prev. 2005;14:1188–93.CrossRef

23.

Yu K, Zhang J, Zhang J, Dou C, Gu S, Xie Y, et al. Methionine synthase A2756G polymorphism and cancer risk: a meta-analysis. Eur J Hum Genet EJHG. 2010;18:370–8.CrossRefPubMed

24.

Van der Put NM, van der Molen EF, Kluijtmans LA, Heil SG, Trijbels JM, Eskes TK, et al. Sequence analysis of the coding region of human methionine synthase: relevance to hyperhomocysteinaemia in neural-tube defects and vascular disease. QJM Mon J Assoc Physicians. 1997;90:511–7.CrossRef

25.

Yates Z, Lucock M. Methionine synthase polymorphism A2756G is associated with susceptibility for thromboembolic events and altered B vitamin/thiol metabolism. Haematologica. 2002;87:751–6 (discussion 756).PubMed

26.

Mir MM, Dar JA, Dar NA, Dar MS, Salam I, Lone MM, et al. Combined impact of polymorphism of folate metabolism genes; glutamate carboxypeptidase, methylene tetrahydrofolate reductase and methionine synthase reductase on breast cancer susceptibility in kashmiri women. Int J Health Sci. 2008;2:3–14.

27.

Rai V, Yadav U, Kumar P. MTRR A66G polymorphism among two caste groups of Uttar Pradesh (India). Indian J Med Sci. 2012;66:136–40.CrossRefPubMed

28.

Kim DJ, Park BL, Koh J-M, Kim GS, Kim LH, Cheong HS, et al. Methionine synthase reductase polymorphisms are associated with serum osteocalcin levels in postmenopausal women. Exp Mol Med. 2006;38:519–24.CrossRefPubMed

29.

Naushad SM, Jain Jamal MN, Prasad CK, Rama Devi AR. Relationship between methionine synthase, methionine synthase reductase genetic polymorphisms and deep vein thrombosis among South Indians. Clin Chem Lab Med. 2008;46:73–9.CrossRefPubMed

30.

Hu S, Liu H-C, Xi S-M. Methionine synthase reductase A66G polymorphism is not associated with breast cancer susceptibility—a meta-analysis. Asian Pac J Cancer Prev APJCP. 2014;15:3267–71.CrossRefPubMed

31.

Miriuka SG, Langman LJ, Evrovski J, Miner SES, D’Mello N, Delgado DH, et al. Genetic polymorphisms predisposing to hyperhomocysteinemia in cardiac transplant patients. Transpl Int Off J Eur Soc Organ Transplant. 2005;18:29–35.CrossRef

32.

Silaste ML, Rantala M, Sämpi M, Alfthan G, Aro A, Kesäniemi YA. Polymorphisms of key enzymes in homocysteine metabolism affect diet responsiveness of plasma homocysteine in healthy women. J Nutr. 2001;131:2643–7.CrossRefPubMed

33.

James HM, Gillis D, Hissaria P, Lester S, Somogyi AA, Cleland LG, et al. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. J Rheumatol. 2008;35:562–71.PubMed

34.

Berkun Y, Abou Atta I, Rubinow A, Orbach H, Levartovsky D, Aamar S, et al. 2756GG genotype of methionine synthase reductase gene is more prevalent in rheumatoid arthritis patients treated with methotrexate and is associated with methotrexate-induced nodulosis. J Rheumatol. 2007;34:1664–9.PubMed

35.

Ghodke Y, Chopra A, Shintre P, Puranik A, Joshi K, Patwardhan B. Profiling single nucleotide polymorphisms (SNPs) across intracellular folate metabolic pathway in healthy Indians. Indian J Med Res. 2011;133:274–9.PubMedPubMedCentral

36.

Rai PS, Murali TS, Vasudevan TG, Prasada SK, Bhagavath AK, Pai P, et al. Genetic variation in genes involved in folate and drug metabolism in a south Indian population. Indian J Hum Genet. 2011;17(Suppl 1):S48–53.CrossRefPubMedPubMedCentral

37.

Burzynski M, Duriagin S, Mostowska M, Wudarski M, Chwalinska-Sadowska H, Jagodzinski PP. MTR 2756 A>G polymorphism is associated with the risk of systemic lupus erythematosus in the Polish population. Lupus. 2007;16:450–4.CrossRefPubMed

38.

Rincón JFM, Cano DL, Morales SJ, Jiménez MLR, Cobos REB, Bello JR. The functional PTPN22 C1858T polymorphism confers risk for rheumatoid arthritis in patients from Central Mexico. Clin Rheumatol. 2016;35:1457–62.CrossRefPubMed

39.

Raslan HM, Attia HR, Salama I, Ibrahim MH, Hassan EM, El Hussieny MS, et al. Association of PTPN22 1858C → T polymorphism, HLA-DRB1 shared epitope and autoantibodies with rheumatoid arthritis. Rheumatol Int. 2016;36:1167–75.CrossRefPubMed

40.

Chen Y, Dawes PT, Packham JC, Mattey DL. Interaction between smoking and functional polymorphism in the TGFB1 gene is associated with ischaemic heart disease and myocardial infarction in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther. 2012;14:R81.CrossRefPubMedPubMedCentral

41.

Chaabane S, Marzouk S, Akrout R, Ben Hamad M, Achour Y, Rebai A, et al. Genetic determinants of methotrexate toxicity in tunisian patients with rheumatoid arthritis: a study of polymorphisms involved in the MTX metabolic pathway. Eur J Drug Metab Pharmacokinet. 2016;41:385–93.CrossRefPubMed

42.

Stamp LK, Chapman PT, O’Donnell JL, Zhang M, James J, Frampton C, et al. Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate. Pharmacogenet Genomics. 2010;20:367–76.CrossRefPubMed

43.

Wessels JAM, van der Kooij SM, le Cessie S, Kievit W, Barerra P, Allaart CF, et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum. 2007;56:1765–75.CrossRefPubMed

Titel: Nonassociation of homocysteine gene polymorphisms with treatment outcome in South Indian Tamil Rheumatoid Arthritis patients
verfasst von: Niveditha Muralidharan
Reena Gulati
Durga Prasanna Misra
Vir S. Negi
Publikationsdatum: 18.08.2017
Verlag: Springer International Publishing
Erschienen in: Clinical and Experimental Medicine / Ausgabe 1/2018
Print ISSN: 1591-8890
Elektronische ISSN: 1591-9528
DOI: https://doi.org/10.1007/s10238-017-0469-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Nonassociation of homocysteine gene polymorphisms with treatment outcome in South Indian Tamil Rheumatoid Arthritis patients

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

DNA methylation profiles in cancer diagnosis and therapeutics

Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?

Globulin–platelet model predicts significant fibrosis and cirrhosis in CHB patients with high HBV DNA and mildly elevated alanine transaminase levels

Assessing liver proteins and enzymes of medical workers exposed to ionizing radiation (IR)

Circulating fibroblast growth factor 21 in patients with liver cirrhosis

Telomere length in the gastric mucosa after Helicobacter pylori eradication and its potential role in the gastric carcinogenesis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin